Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Hormones – e.g. – prolactin – thymosin – growth factors – etc.
Reexamination Certificate
2006-02-28
2006-02-28
Spector, Lorraine (Department: 1646)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Hormones, e.g., prolactin, thymosin, growth factors, etc.
C530S350000, C530S300000
Reexamination Certificate
active
07005505
ABSTRACT:
The present invention involves the preparation of vascular endothelial growth actor (VEGF) variants which provide materials that are selective in respect to binding characteristics to the kinase domain region and the FMS-like tyrosine-kinase region, respectively KDR and FLT-1. The respective KDR and FLT-1 receptors are bound by corresponding domains within the VEGF compound domains. The variants hereof define those two binding regions and modify them so as to introduce changes that interrupt the binding to the respective domain. In this fashion the final biological characteristics of the VEGF molecule are selectively modified.
REFERENCES:
patent: 3691016 (1972-09-01), Patel
patent: 3773919 (1973-11-01), Boswell et al.
patent: 3887699 (1975-06-01), Yolles
patent: 3969287 (1976-07-01), Jaworek et al.
patent: 4195128 (1980-03-01), Hildebrand et al.
patent: 4229537 (1980-10-01), Hodgins et al.
patent: 4247642 (1981-01-01), Hirohara et al.
patent: 4330440 (1982-05-01), Ayers et al.
patent: 4399216 (1983-08-01), Axel et al.
patent: 5073492 (1991-12-01), Chen et al.
patent: 5219739 (1993-06-01), Tischer et al.
patent: 5332671 (1994-07-01), Ferrara et al.
patent: 6057428 (2000-05-01), Keyt et al.
patent: 1 176 565 (1984-10-01), None
patent: 0 058 481 (1981-08-01), None
patent: 0 036 776 (1981-09-01), None
patent: 0 075 444 (1983-03-01), None
patent: 0 133 988 (1985-03-01), None
patent: 0 158 277 (1985-10-01), None
patent: 0 160 457 (1985-11-01), None
patent: 0 266 032 (1988-05-01), None
patent: 0 506 477 (1990-09-01), None
patent: WO 87/05330 (1987-09-01), None
patent: WO 90/13649 (1990-11-01), None
GenBank Database, Liang et al. ‘vascular endothelial growth factor isoform 165 [Danio rerio]’ Apr. 1998, Accession No. AAC41274.
GenBank Database, Eichmann et al. ‘vascular endothelial growth factor C [Coturnix coturnix]’ May 1998, Accession No. CAA75799.
GenBank Database, Cleaver et al. ‘vascular endothelial growth factor 1996 [Xenopus laevis]’ Jul. 1997, Accession No. AAB63680.
GenBank Database, Junqueira de Azevedo et al. ‘vascular endothelial growth factor precursor [Bothrops jararaca]’ Oct. 2001, Accession No. AAK52103.
GenBank Database, Meyer et al. ‘vascular endothelial growth factor homolog Vefg-e [Orf virus]’ Mar. 1999, Accession No. AAD03735.
Potgens et al., Covalent dimerization of vascular permeability factor/vascular endothelial growth factor is essential for its biological activity:Evidence from cys to ser mutations, J. Biol. Chem., 269(52):32879-32885, Dec. 30, 1994.
Adelman et al., “In Vitro Deletional Mutagenesis for Bacterial Production of the 20,000-Dalton Form of Human Pituitary Growth Hormone,”DNA2(3):183-193 (1983).
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”New England J of Medicine331(22):1480-1487 (1994).
Alpin et al., “Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids,”CRC Crit. Rev. Biochem.10(4):259-306 (1981).
Aviv et al., “Purification of Biologically Active Globin Messenger RNA by Chromatography on Oligothymidylic Acid-Cellulose,”Pro. Natl. Acad. Sci. USA69(6):1408-1412 (1972).
Baenziger, “The Oligosaccharides of Plasma Glycoproteins: Synthesis, Structure, and Function,” inThe Plasma Proteins: Structure, Function, and Genetic Control, F.W. Putnam, eds. 2d edition, Academic Press: New York, vol. IV, Chapter 5, pp. 271-315 (1984).
Barzu et al., “Binding and endocytosis of heparin by human endothelial cells in culture,”Biochimica et Biophysica Acta845:196-203 (1985).
Benton et al., “Screening λgt recombinant clones by hybridization to single plaques in situ,”Science196:180-182 (1977).
Bolivar et al., “Construction and Characterization of New Clonig Vehicles. II. A Multipurpose Cloning System,”Gene2:95-113 (1977).
Bothwell et al., “Dual expression of λ genes in the MOPC-315 plasmacytoma,”Nature290:65-67 (1981).
Breir et al., “Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation,”Dev,114:521-532 (1992).
Chang, “Are World Summits Really Necessary,”Nature375:615 (1978).
Chen et al., “High-efficiency transformation of mammalian cells by plasmid DNA,”Mol. Cell. Biol.7(8):2745-2752 (1987).
Cohen, et al., “Nonchromosomal Antibiotic Resistance in Bacteria: Genetic Transformation ofEscherichia coliby R-Factor DNA,”Proc. Natl. Acad. Sci. USA69(8):2110-2114 (1972).
Crea et al., “Chemical Synthesis of Genes for Human Insulin,”Proc. Natl. Acad. Sci. USA75(12):5765-5769 (1978).
Creighton, T.E.,Proteins: Structure and Molecular Principles, W.H. Freeman & Co.: San Francisco pp. 79-86 (1983).
Ferrara et al., “Pituitary Follicular Cells Secrete a Novel Heparin-binding Growth Factor Specific for Vascular Endothelial Cells.”Biochem.&Biophys. Res. Comm.161(2):851-858 (1989).
Ferrara, N., “Vascular endothelial growth factor. The trigger for neovascularization in the eye,”Laboratory Investigation72(6):615-618 (1995).
Fiers et al., “Complete Nucleotide Sequences of SV40 DNA,”Nature273:113-120 (1990).
Froehler, et al., “Synthesis of DNA via Deoxynucleoside H-phosphonate Intermediates,”Nucleic Acids Research14(13):5399-5407 (1986).
George et al., “Mutation data matrix and its uses,”Meth. Enzymol.183:333-351 (1990).
Goeddel et al., “Direct Expression inEscherichia coliof a DNA Sequence Coding for Human Growth Hormone,”Nature281:544-548 (1979).
Goeddel et al., “Synthesis of Human Fibroblast Interferon byE. coli,” Nucleic Acids Research8(18):4057-4074 (1980).
Gorman et al., “Transient Production of Proteins Using an Andenovirus Transformed Cell Line,”DNA Prot. Eng. Tech.2(1):3-10 (1990).
Graham et al., “A New Technique for the Assay of Infectivity of Human Adenovirus 5 DNA,”Virology52:456-467 (1973).
Green, et al., “Human β-globin pre-mRNA synthesized in vitro is accurately spliced inXenopus oocytenuclei,”Cell32(3):681-694 (1983).
Haniu et al., “Disulfide bonds in recombinant human platelet-derived growth factor BB dimer: characterization of intermolecular and intramolecular disulfide linkages,”Biochemistry32:2431-2437 (1993).
Hess et al., “Cooperation of Glycolytic Enzymes,”Advances in Enzyme RegulationGeorge Weber , New York: Pergamon Press, vol. 7, pp. 149-167 (1968).
Hitzeman et al., “Isolation and Characterization of the Yeast 3-Phosphoglycerokinase Gene (PGK) by an Immunological Screening Technique,”Journal of Biological Chemistry255(24):12073-12080 (1980).
Holland et al., “Isolation and Identification of Yeast Messenger Ribonucleic Acids Coding for Enolase, Glyceraldehyde-3-phosphate Dehydrogenase, and Phosphoglycerate Kinase,”Biochemistry17(23):4900-4907 (1978).
Houck et al., “Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms,”Journal of Biological Chemistry267:26031-26037 (1992).
Hsiao, et al., “High-frequency Transformation of Yeast by Plasmids Containing the Cloned Yeast Arg4Gene,”Proc. Natl. Acad. Sci. USA76:3829-3833 (1979).
Hunter et al., “Preparation of Iodine 131 Labelled Human Growth Hormone of High Specific Activity,”Nature194:495-496 (1962).
Huynh, et al., “Constructing and Screening cDNA Libraries in λgt10 and λgt11,”DNA Cloning; A Practical Approach, D.M. Glover, vol. 1, pp. 49-78 (1985).
Itakura et al., “Expression inEscherichia coliof a Chemically Synthesized Gene for the Hormone Somatostatin,”Science198:1056-1063 (1977).
Jones, E., “Proteinase Mutants ofSaccharomycess cerevisiae,” Genetics85(1):23-33 (1977).
Kendall et al., “Specificity
Ferrara Napoleone
Keyt Bruce A.
Nguyen Francis Hung
Genentech Inc.
Kaufman Claire M.
Merchant & Gould P.C.
Spector Lorraine
LandOfFree
Variants of vascular endothelial cell growth factor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Variants of vascular endothelial cell growth factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Variants of vascular endothelial cell growth factor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3687629